CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments

1.3.1. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets

3.3. Top winning strategies, 2017
3.4. Top player positioning, 2017
3.5. Porters five forces analysis
3.6. Market dynamics

3.6.1. Drivers

3.6.1.1. Increase in incidence of chronic and infectious diseases
3.6.1.2. Technological advancements in IVD
3.6.1.3. Emergence of minimal invasive technologies
3.6.1.4. Increasing government expenditures on healthcare
3.6.1.5. Increase in popularity of personalized medicine approach

3.6.2. Restraint

3.6.2.1. Unclear reimbursement policies
3.6.2.2. Stringent regulatory policies

3.6.3. Opportunities

3.6.3.1. Potential opportunities for outsourcing
3.6.3.2. Convergence of new technologies

3.6.4. Impact Analyses

CHAPTER 4: IN-VITRO DIAGNOSTICS MARKET, BY PRODUCT TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. Reagents

4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country

4.3. Instruments

4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country

4.4. Software & Services

4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country

CHAPTER 5: IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

5.1. Overview

5.1.1. Market size and forecast

5.2. Immunodiagnostics

5.2.1. Market size and forecast, by type

5.2.1.1. Enzyme-Linked Immunosorbent Assay (ELISA)

5.2.1.1.1. Market size and forecast
5.2.1.1.2. Chemiluminescence Immunoassay (CLIA)

5.2.1.1.2.1. Market size and forecast

5.2.1.1.3. Fluorescence Immunoassay (FIA)

5.2.1.1.3.1. Market size and forecast

5.2.1.1.4. Colorimetric Immunoassay (CI)

5.2.1.1.4.1. Market size and forecast

5.2.1.2. Rapid Tests

5.2.1.2.1. Market size and forecast

5.2.1.3. Enzyme-Linked ImmunoSpot (ELISPOT)

5.2.1.3.1. Market size and forecast

5.2.1.4. Radioimmunoassay (RIA)

5.2.1.4.1. Market size and forecast

5.2.1.5. Western Blot

5.2.1.5.1. Market size and forecast

5.2.2. Market size and forecast, by region
5.2.3. Market analysis, by country

5.3. Hematology

5.3.1. Market size and forecast, by region
5.3.2. Market share analysis, by country

5.4. Molecular Diagnostics

5.4.1. Market size and forecast, by type

5.4.1.1. Polymerize Chain Reaction (PCR)

5.4.1.1.1. Market size and forecast

5.4.1.2. Isothermal Nucleic Acid Technology (INAAT)

5.4.1.2.1. Market size and forecast

5.4.1.3. Hybridization

5.4.1.3.1. Market size and forecast

5.4.1.4. DNA Diagnostics

5.4.1.4.1. Market size and forecast

5.4.1.5. Microarray

5.4.1.5.1. Market size and forecast

5.4.1.6. Others

5.4.1.6.1. Market size and forecast

5.4.2. Market size and forecast, by region
5.4.3. Market share analysis, by country

5.5. Tissue Diagnostics

5.5.1. Market size and forecast, by region
5.5.2. Market share analysis, by country

5.6. Clinical Chemistry

5.6.1. Market size and forecast, by type

5.6.1.1. Basic Metabolic Panel

5.6.1.1.1. Market size and forecast

5.6.1.2. Liver Panel

5.6.1.2.1. Market size and forecast

5.6.1.3. Renal Profile

5.6.1.3.1. Market size and forecast

5.6.1.4. Lipid Profile

5.6.1.4.1. Market size and forecast

5.6.1.5. Thyroid Function Panel

5.6.1.5.1. Market size and forecast

5.6.1.6. Electrolyte Panel

5.6.1.6.1. Market size and forecast

5.6.1.7. Specialty Chemicals

5.6.1.7.1. Market size and forecast

5.6.2. Market size and forecast, by region
5.6.3. Market share analysis, by country

5.7. Others

5.7.1. Market size and forecast, by region
5.7.2. Market share analysis, by country

CHAPTER 6: IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

6.1. Overview

6.1.1. Market size and forecast

6.2. Infectious Diseases

6.2.1. Market size and forecast, by region
6.2.2. Market share analysis

6.3. Cancer

6.3.1. Market size and forecast, by region
6.3.2. Market share analysis, by country

6.4. Cardiac Diseases

6.4.1. Market size and forecast, by region
6.4.2. Market share analysis, by country

6.5. Immune System Disorders

6.5.1. Market size and forecast, by region
6.5.2. Market share analysis, by country

6.6. Nephrological Diseases

6.6.1. Market size and forecast, by region
6.6.2. Market share analysis

6.7. Gastrointestinal Diseases

6.7.1. Market size and forecast, by region
6.7.2. Market share analysis

6.8. Others

6.8.1. Market size and forecast, by region
6.8.2. Market share analysis

CHAPTER 7: IN-VITRO DIAGNOSTICS MARKET, BY END USER

7.1. Overview

7.1.1. Market size and forecast

7.2. Stand-Alone Laboratory

7.2.1. Market size and forecast, by region
7.2.2. Market share analysis, by country

7.3. Hospitals

7.3.1. Market size and forecast, by region
7.3.2. Market share analysis, by country

7.4. Academic & Medical Schools

7.4.1. Market size and forecast, by region
7.4.2. Market share analysis

7.5. Point of Care Testing

7.5.1. Market size and forecast, by region
7.5.2. Market share analysis

7.6. Others

7.6.1. Market size and forecast, by region
7.6.2. Market share analysis, by country

CHAPTER 8: IN-VITRO DIAGNOSTICS MARKET, BY REGION

8.1. Overview

8.1.1. Market size and forecast

8.2. North America

8.2.1. Key market trends, growth factors, and opportunities
8.2.2. Market size and forecast, by country

8.2.2.1. U.S.

8.2.2.1.1. U.S. In-vitro diagnostics market, by product type
8.2.2.1.2. U.S. In-vitro diagnostics market, by technique
8.2.2.1.3. U.S. In-vitro diagnostics market, by application
8.2.2.1.4. U.S. In-vitro diagnostics market, by end user

8.2.2.2. Canada

8.2.2.2.1. Canada In-vitro diagnostics market, by product type
8.2.2.2.2. Canada In-vitro diagnostics market, by technique
8.2.2.2.3. Canada In-vitro diagnostics market, by application
8.2.2.2.4. Canada In-vitro diagnostics market, by end user

8.2.2.3. Mexico

8.2.2.3.1. Mexico In-vitro diagnostics market, by product type
8.2.2.3.2. Mexico In-vitro diagnostics market, by technique
8.2.2.3.3. Mexico In-vitro diagnostics market, by application
8.2.2.3.4. Mexico In-vitro diagnostics market, by end user

8.2.3. Market size and forecast, by product type
8.2.4. Market size and forecast, by technique
8.2.5. Market size and forecast, by application
8.2.6. Market size and forecast, by end user

8.3. Europe

8.3.1. Key market trends, growth factors, and opportunities
8.3.2. Market size and forecast, by country

8.3.2.1. Germany

8.3.2.1.1. Germany In-vitro diagnostics market, by product type
8.3.2.1.2. Germany In-vitro diagnostics market, by technique
8.3.2.1.3. Germany In-vitro diagnostics market, by application
8.3.2.1.4. Germany In-vitro diagnostics market, by end user

8.3.2.2. France

8.3.2.2.1. France In-vitro diagnostics market, by product type
8.3.2.2.2. France In-vitro diagnostics market, by technique
8.3.2.2.3. France In-vitro diagnostics market, by application
8.3.2.2.4. France In-vitro diagnostics market, by end user

8.3.2.3. UK

8.3.2.3.1. UK In-vitro diagnostics market, by product type
8.3.2.3.2. UK In-vitro diagnostics market, by technique
8.3.2.3.3. UK In-vitro diagnostics market, by application
8.3.2.3.4. UK In-vitro diagnostics market, by end user

8.3.2.4. Italy

8.3.2.4.1. Italy In-vitro diagnostics market, by product type
8.3.2.4.2. Italy In-vitro diagnostics market, by technique
8.3.2.4.3. Italy In-vitro diagnostics market, by application
8.3.2.4.4. Italy In-vitro diagnostics market, by end user

8.3.2.5. Spain

8.3.2.5.1. Spain In-vitro diagnostics market, by product type
8.3.2.5.2. Spain In-vitro diagnostics market, by technique
8.3.2.5.3. Spain In-vitro diagnostics market, by application
8.3.2.5.4. Spain In-vitro diagnostics market, by end user

8.3.2.6. Rest of Europe

8.3.2.6.1. Rest of Europe In-vitro diagnostics market, by product t type
8.3.2.6.2. Rest of Europe In-vitro diagnostics market, by technique
8.3.2.6.3. Rest of Europe In-vitro diagnostics market, by application
8.3.2.6.4. Rest of Europe In-vitro diagnostics market, by end user

8.3.3. Market size and forecast, by product type
8.3.4. Market size and forecast, by technique
8.3.5. Market size and forecast, by application
8.3.6. Market size and forecast, by end user

8.4. Asia-Pacific

8.4.1. Key market trends, growth factors, and opportunities
8.4.2. Market size and forecast, by country

8.4.2.1. Japan

8.4.2.1.1. Japan In-vitro diagnostics market, by product type
8.4.2.1.2. Japan In-vitro diagnostics market, by technique
8.4.2.1.3. Japan In-vitro diagnostics market, by application
8.4.2.1.4. Japan In-vitro diagnostics market, by end user

8.4.2.2. China

8.4.2.2.1. China In-vitro diagnostics market, by product type
8.4.2.2.2. China In-vitro diagnostics market, by technique
8.4.2.2.3. China In-vitro diagnostics market, by application
8.4.2.2.4. China In-vitro diagnostics market, by end user

8.4.2.3. Australia

8.4.2.3.1. Australia In-vitro diagnostics market, by product type
8.4.2.3.2. Australia In-vitro diagnostics market, by technique
8.4.2.3.3. Australia In-vitro diagnostics market, by application
8.4.2.3.4. Australia In-vitro diagnostics market, by end user

8.4.2.4. India

8.4.2.4.1. India In-vitro diagnostics market, by product type
8.4.2.4.2. India In-vitro diagnostics market, by technique
8.4.2.4.3. India In-vitro diagnostics market, by application
8.4.2.4.4. India In-vitro diagnostics market, by end user

8.4.2.5. South Korea

8.4.2.5.1. South Korea In-vitro diagnostics market, by product type
8.4.2.5.2. South Korea In-vitro diagnostics market, by technique
8.4.2.5.3. South Korea In-vitro diagnostics market, by application
8.4.2.5.4. South Korea In-vitro diagnostics market, by end user

8.4.2.6. Rest of Asia-Pacific

8.4.2.6.1. Rest of Asia-Pacific In-vitro diagnostics market, by product type
8.4.2.6.2. Rest of Asia-Pacific In-vitro diagnostics market, by technique
8.4.2.6.3. Rest of Asia-Pacific In-vitro diagnostics market, by application
8.4.2.6.4. Rest of Asia-Pacific In-vitro diagnostics market, by end user

8.4.3. Market size and forecast, by product type
8.4.4. Market size and forecast, by technique
8.4.5. Market size and forecast, by indication
8.4.6. Market size and forecast, by end user

8.5. LAMEA

8.5.1. Key market trends, growth factors, and opportunities
8.5.2. Market size and forecast, by country

8.5.2.1. Brazil

8.5.2.1.1. Brazil In-vitro diagnostics market, by product type
8.5.2.1.2. Brazil In-vitro diagnostics market, by technique
8.5.2.1.3. Brazil In-vitro diagnostics market, by application
8.5.2.1.4. Brazil In-vitro diagnostics market, by end user

8.5.2.2. Saudi Arabia

8.5.2.2.1. Saudi Arabia In-vitro diagnostics market, by product type
8.5.2.2.3. Saudi Arabia In-vitro diagnostics market, by technique
8.5.2.2.4. Saudi Arabia In-vitro diagnostics market, by application
8.5.2.2.5. Saudi Arabia In-vitro diagnostics market, by end user

8.5.2.3. South Africa

8.5.2.3.1. South Africa In-vitro diagnostics market, by product type
8.5.2.3.2. South Africa In-vitro diagnostics market, by technique
8.5.2.3.3. South Africa In-vitro diagnostics market, by application
8.5.2.3.4. South Africa In-vitro diagnostics market, by end user

8.5.2.4. Rest of LAMEA

8.5.2.4.1. Rest of LAMEA In-vitro diagnostics market, by product type
8.5.2.4.2. Rest of LAMEA In-vitro diagnostics market, by technique
8.5.2.4.3. Rest of LAMEA In-vitro diagnostics market, by application
8.5.2.4.4. Rest of LAMEA In-vitro diagnostics market, by end user

8.5.3. Market size and forecast, by product type
8.5.4. Market size and forecast, by technique
8.5.5. Market size and forecast, by application
8.5.6. Market size and forecast, by end user

CHAPTER 9: COMPANY PROFILES

9.1. Abbott Laboratories

9.1.1. Company overview
9.1.2. Company snapshot
9.1.3. Operating business segments
9.1.4. Product type Portfolio
9.1.5. Business performance
9.1.6. Key strategic moves and developments

9.2. Becton, Dickinson and Company

9.2.1. Company overview
9.2.2. Company snapshot
9.2.3. Operating business segments
9.2.4. Product type Portfolio
9.2.5. Business performance
9.2.6. Key strategic moves and developments

9.3. bioMrieux SA

9.3.1. Company overview
9.3.2. Company snapshot
9.3.3. Product type portfolio
9.3.4. Business performance
9.3.5. Key strategic moves and developments

9.4. Bio-Rad Laboratories, Inc.

9.4.1. Company overview
9.4.2. Company snapshot
9.4.3. Operating business segments
9.4.4. Product type Portfolio
9.4.5. Business performance
9.4.6. Key strategic moves and developments

9.5. Danaher Corporation (Beckman Coulter, Inc.)

9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Operating business segments
9.5.4. Product type portfolio
9.5.5. Business performance
9.5.6. Key strategic moves and developments

9.6. F. Hoffmann-La Roche Ltd.

9.6.1. Company overview
9.6.2. Company snapshot
9.6.3. Operating business segments
9.6.4. Product type portfolio
9.6.5. Business performance
9.6.6. Key strategic moves and developments

9.7. Johnson & Johnson

9.7.1. Company overview
9.7.2. Company snapshot
9.7.3. Operating business segments
9.7.4. Product type Portfolio
9.7.5. Business performance
9.7.6. Key strategic moves and developments

9.8. QIAGEN N.V.

9.8.1. Company overview
9.8.2. Company snapshot
9.8.3. Product type portfolio
9.8.4. Business performance

9.9. Sysmex Corporation

9.9.1. Company overview
9.9.2. Company snapshot
9.9.3. Operating business segments
9.9.4. Product type Portfolio
9.9.5. Business performance

9.10. Thermo Fisher Scientific, Inc.

9.10.1. Company overview
9.10.2. Company snapshot
9.10.3. Operating business segments
9.10.4. Product type Portfolio
9.10.5. Business performance
9.10.6. Key strategic moves and developments